Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

被引：0

作者：

van de Donk, Niels W. C. J. ^{[1
]}

Chari, Ajai ^{[2
]}

Karlin, Lionel ^{[3
]}

Krishnan, Amrita Y. ^{[4
]}

Uttervall, Katarina ^{[5
]}

Chalopin, Thomas ^{[6
]}

Dachs, Laura Rosinol ^{[7
]}

Oriol, Albert ^{[8
,9
]}

Matous, Jeffrey, V ^{[10
]}

Bhutani, Manisha ^{[11
]}

Rodriguez, Cesar ^{[12
]}

Carde, Natalia Quijano ^{[13
]}

Guo, Yue ^{[13
]}

Hodin, Caroline ^{[14
]}

Uhlar, Clarissa ^{[13
]}

Stephenson, Tara ^{[13
]}

Zuppa, Athena ^{[15
]}

Doyle, Margaret ^{[16
]}

Chastain, Katherine ^{[15
]}

Garfall, Alfred ^{[17
]}

机构：

[1] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands

[2] Univ Calif San Francisco, San Francisco, CA USA

[3] Ctr Hosp Lyon Sud, Pierre Benite, France

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Karolinska Univ Hosp, Stockholm, Sweden

[6] Ctr Hosp Univ Tours, Tours, France

[7] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[8] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[9] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[10] Sarah Cannon Res Inst, Colorado Blood Canc Inst, Denver, CO USA

[11] Atrium Hlth, Levine Canc Inst, Wake Forest Sch Med, Charlotte, NC USA

[12] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med Hematol & Med Oncol, New York, NY USA

[13] Janssen Res & Dev, Spring House, PA USA

[14] Janssen Res & Dev, Beerse, Belgium

[15] Janssen Res & Dev, Raritan, NJ USA

[16] Janssen Global Serv, Dublin, Ireland

[17] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200344

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4735 / 4735

页数：1

共 34 条

[1] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
Matous, Jeffrey, V
van de Donk, Niels W. C. J.
Oriol, Albert
Garfall, Alfred L.
Rodriguez-Otero, Paula
Chalopin, Thomas
Dachs, Laura Rosinol
Uttervall, Katarina
Mateos, Maria- Victoria
Trancucci, Danielle
Carde, Natalia Quijano
Hodin, Caroline
Stephenson, Tara
Zuppa, Athena
Chastain, Katherine
Karlin, Lionel
BLOOD, 2024, 144 : 4749 - 4750
[2] MANAGING CYTOKINE RELEASE SYNDROME IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXPERIENCE WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY
Catamero, Donna
Blazquez, Patricia
Shenoy, Samantha
Chastain, Katherine
Kruyswijk, Sandy
ONCOLOGY NURSING FORUM, 2023, 50 (02)
[3] Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study
Catamero, Donna
Benito, Patricia Blazquez
Shenoy, Samantha
Chastain, Katherine
Kruyswijk, Sandy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S315 - S316
[4] Nursing Considerations for Cytokine Release Syndrome in Relapsed/ Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study
Catamero, Donna
Benito, Patricia Blazquez
Shenoy, Samantha
Doyle, Margaret
Fowler, Jessica
Kobos, Rachel
Banerjee, Arnob
Kruyswijk, Sandy
SEMINARS IN ONCOLOGY NURSING, 2024, 40 (03)
[5] Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
Rosinol, Laura
Garfall, Alfred
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
van de Donk, Niels
Matous, Jeffrey
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos Manteca, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S84 - S85
[6] Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
Usmani, Saad Z.
Karlin, Lionel
Benboubker, Lotfi
Nahi, Hareth
San-Miguel, Jesus
Trancucci, Danielle
Qi, Keqin
Stephenson, Tara
Puchalt, Alfredo Perales
Chastain, Katherine
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S477
[7] Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Martin, Thomas G.
Mateos, Maria Victoria
Nooka, Ajay
Banerjee, Arnob
Kobos, Rachel
Pei, Lixia
Qi, Ming
Verona, Raluca
Doyle, Margaret
Smit, Jennifer
Sun, Weili
Trancucci, Danielle
Uhlar, Clarissa
van de Donk, Niels W. C. J.
Rodriguez, Cesar
CANCER, 2023, 129 (13) : 2035 - 2046
[8] Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing
Korst, Charlotte L. B. M.
Groen, Kaz
Bosman, Patricia W. C.
van der Valk, Fleur
Verkleij, Christie P. M.
Kruyswijk, Sandy
de Ruijter, Maaike E. M.
Heijink, Dianne M.
Kuipers, Maria T.
Zweegman, Sonja
van de Donk, Niels W. C. J.
HEMASPHERE, 2024, 8 (07):
[9] Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
Usmani, Saad Zafar
Karlin, Lionel
Benboubker, Lotfi
Nahi, Hareth
San-Miguel, Jesus
Trancucci, Danielle
Qi, Keqin
Stephenson, Tara
Perales-Puchalt, Alfredo
Chastain, Katherine
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
Rosinol, Laura
Matous, Jeffrey V.
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S549

← 1 2 3 4 →